KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In Process
Ratios

CRISPR Therapeutics AG (CRSP) Leases (2019 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Leases for 7 consecutive years, with $131.7 million as the latest value for Q4 2025.

  • Quarterly Leases fell 8.18% to $131.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $131.7 million through Dec 2025, down 8.18% year-over-year, with the annual reading at $131.7 million for FY2025, 8.18% down from the prior year.
  • Leases hit $131.7 million in Q4 2025 for CRISPR Therapeutics AG, down from $134.7 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $179.4 million in Q2 2021 to a low of $50.1 million in Q1 2021.
  • Historically, Leases has averaged $149.6 million across 5 years, with a median of $153.7 million in 2023.
  • Biggest five-year swings in Leases: soared 356.48% in 2021 and later dropped 10.61% in 2023.
  • Year by year, Leases stood at $174.5 million in 2021, then dropped by 10.05% to $156.9 million in 2022, then dropped by 1.87% to $154.0 million in 2023, then fell by 6.84% to $143.5 million in 2024, then fell by 8.18% to $131.7 million in 2025.
  • Business Quant data shows Leases for CRSP at $131.7 million in Q4 2025, $134.7 million in Q3 2025, and $137.6 million in Q2 2025.